| Date Filed | Type | Description |
| 08/14/2023 |
4
| Tasse Daniel (CEO) has filed a Form 4 on DBV Technologies S.A.|
Txns:
| Granted 764,386 options to buy
@ $0 |
|
| 08/14/2023 |
4
| Mohideen Pharis (Chief Medical Officer) has filed a Form 4 on DBV Technologies S.A.|
Txns:
| Granted 10,000 shares
@ $0
Granted 17,500 shares
@ $0
Sold 1,792 shares
@ $2.88, valued at
$5.2k
Sold 469 shares
@ $3.54, valued at
$1.7k
Granted 100,000 options to buy
@ $0
Granted 115,000 options to buy
@ $0 |
|
| 08/14/2023 |
4
| Robitaille Sebastien (CFO) has filed a Form 4 on DBV Technologies S.A.|
Txns:
| Granted 8,000 shares
@ $0
Granted 65,000 options to buy
@ $0 |
|
| 08/03/2023 |
4
| SOLAND DANIEL B (Director) has filed a Form 4 on DBV Technologies S.A.|
Txns:
| Bought 15,000 shares
@ $1.62, valued at
$24.3k
|
|
| 07/31/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/11/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/06/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/08/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G
| BRAIDWELL LP reports a 10% stake in DBV TECHNOLOGIES S.A. |
| 12/23/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/06/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/11/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/11/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/01/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/01/2022 |
8-K
| Quarterly results|
Docs:
|
"Three months ended June 30, Six months ended June 30, Six months ended June 30, 2022 2021 2022 2021 2022 2021 Net $ $ $ $ $ $ Basic / diluted net loss per share $ $ $ $ $ $ For the three months ended June 30, 2022, net loss was $ million compared to a net loss of $ million for the comparable period in 2021. On a per share basis, net loss was $ and $ for the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022, net loss was $ million and $ million under U.S. GAAP and IFRS, respectively. Net loss per share was $ under U.S. GAAP and $ under IFRS. Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of June 30, 2022: Total number of shares Total number of voting rights 06/30/2022 94,022,679 Tota..." |
|
| 07/18/2022 |
F-6EF
| Form F-6EF - Registration of American Depository Receipt shares, immediately effective: |
| 06/23/2022 |
SC 13G
| Venrock Healthcare Capital Partners II, L.P. reports a 9.9% stake in DBV Technologies S.A. |
| 06/16/2022 |
SC 13D/A
| Bpifrance Participations SA reports a 7.6% stake in DBV Technologies S.A. |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/13/2022 |
8-K
| Quarterly results |
|